Inflammatory bowel disease is one of the most challenging areas of development. The competition for sites and patients is fierce. Screen fail rates are high. And showing clear evidence of efficacy is the name of the game.
As a recognized leader in IBD clinical development, IQVIA has extensive experience in helping our customers achieve success – by applying innovative study designs, recruiting patients faster, and showing clear separation of active drug effect from placebo.
Nonalcoholic steatohepatitis (NASH) represents a public health issue around the world, with no current treatment and heavy consequences on healthcare systems. The lack of awareness and effective biomarkers for NASH has resulted in most patients unaware that that they are even at risk for this disease. While competition for sites and patients for clinical trials is intense, the reality of moving patients toward treatments that don’t yet exist is a perfect storm. And it is clouding our ability to truly understand the disease and move the needle, clinically and commercially.
To change the paradigm of clinical development in NASH, and ensure that risk assessments, market access and reimbursement strategies are prepared to address the unique complexities of this disease and patient population, a new approach is needed.
Powered by the IQVIA CORE, IQVIA has built a global network of sites and utilizes predictive analytics to help sites identify patients at highest risk for NASH within their medical records.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
Predict enrollment more accurately and increase the number of patients per site using data-driven patient recruitment solutions.
IQVIA is using vast quantities of data in powerful new ways. See how we can help you tap into information from past trials, patient reported outcomes and other sources to accelerate your research.